Pesquisa de referências

Drilling down on drug prices

Recurso electrónico / Electronic resource
Registro MARC
Tag12Valor
LDR  00000cab a2200000 4500
001  MAP20190021326
003  MAP
005  20190715150850.0
008  190710e20190507usa|||p |0|||b|eng d
040  ‎$a‎MAP‎$b‎spa‎$d‎MAP
084  ‎$a‎931
1001 ‎$0‎MAPA20190009621‎$a‎Passwater, Keith
24500‎$a‎Drilling down on drug prices‎$c‎Keith Passwater, Dave Nelson
300  ‎$a‎8 p.
520  ‎$a‎Extending life and improving quality of life for literally millions, drug treatments such as aspirin, penicillin, insulin, AZT, cancer drug Herceptin, Harvoni, and Lipitor are nothing short of miracle drugs. Recently developed therapies are also impressive, such as single-dose Kymriah, which has an unprecedented 83 percent remission rate for children with acute lymphoblastic leukemia.[1] Another example is the newly available gene therapy Luxturna, which can cure blindness in carefully selected patients. Such therapies can achieve outcomes that are truly miraculous for those cured patients; they can also be staggeringly expensive. While anyone with a heart would agree that these miracle drug benefits are wonderful for patients, we need to find ways to harness these invaluable benefits while also finding ways to curb the growth in drug costs in the U.S. for all partiesconsumers, payers, and manufacturers alike.
650 4‎$0‎MAPA20080606633‎$a‎Industria farmacéutica
650 4‎$0‎MAPA20080579784‎$a‎Costes económicos
650 4‎$0‎MAPA20080621919‎$a‎Precios de los medicamentos
7001 ‎$0‎MAPA20080051983‎$a‎Nelson, Dave
7730 ‎$w‎MAP20190020794‎$t‎Contingencies : American Academy of Actuaries‎$d‎Washington : American Academy of Actuaries, 2019-2024‎$g‎07/05/2019 Año 2019 - May-June , p. 38-45